phase ii trial undertaken determine efficacy toxicity proton beam radiotherapy patients locally unresectable hepatocellular carcinoma cirrhotic patients eligible score NUMBER eligible patients included t NUMBER NUMBER hepatocellular carcinoma selected t NUMBER patients eligible patients lymph node distant metastases ineligible daily proton beam radiotherapy directed liver tumor additional cm margin total dose NUMBER cobalt gray equivalents administered NUMBER divided fractions NUMBER weeks patients completed treatment followed minimum NUMBER months median period NUMBER months mean age NUMBER years average tumor size NUMBER cm posttreatment toxicity included small significant decline albumin levels increased total bilirubin NUMBER experienced duodenal colonic bleeding bowel immediately adjacent treated tumor actuarial data showed NUMBER local tumor control rate overall survival rate NUMBER patients elevated pretreatment NUMBER declining levels pretreatment mean NUMBER NUMBER NUMBER months treatment patients underwent liver transplantation NUMBER NUMBER months completion radiotherapy NUMBER showing evidence residual carcinoma explanted liver overall majority patients responded treatment therapy tolerated child pugh t NUMBER NUMBER thirty follow year alpha fetoprotein alpha fetoprotein